Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

07. Januar 2025 04:30 ET | Quelle: Pentixapharm Holding AG

Pentixapharm Receives EUR 6.77 Million for Intangible Assets Formerly Developed by Glycotope

BERLIN, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Pentixapharm AG, a developer of innovative radiopharmaceuticals, receives 6.77 million Euro for intangible assets formerly developed by Glycotope from...
21. November 2024 05:07 ET | Quelle: Pentixapharm Holding AG

First Patient Treated in Phase I/II Trial in Acute Myeloid and Acute Lymphoblastic Leukemia with Lu177-PentixaTher, Expanding the Evidence Base for Targeted Radiotherapy Approach

BERLIN and WURZBURG, Germany, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pentixapharm Holding AG, a biopharmaceutical company developing innovative first-in-class radiopharmaceuticals, today announced that...
03. Juli 2024 02:30 ET | Quelle: Pentixapharm AG

Pentixapharm Acquires Target Discovery Business of Glycotope

WÜRZBURG, Germany and BERLIN, July 03, 2024 (GLOBE NEWSWIRE) -- Pentixapharm AG, a clinical-stage biotech company discovering and developing novel targeted radiopharmaceuticals against a range...
25. Juni 2024 06:00 ET | Quelle: Pentixapharm AG

Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism

WÜRZBURG, Germany, June 25, 2024 (GLOBE NEWSWIRE) -- Pentixapharm AG, a radiopharmaceutical development company wholly owned by Eckert & Ziegler SE, today announced that it has received...